Dade sells urinalysis tests to Quidel:
This article was originally published in Clinica
US point-of-care diagnostics company Quidel has completed the acquisition of Dade Behring's Rapignost urine test strip business. "Urinalysis tests are important tools for the physician's overall assessment of patient health and will complement Quidel's existing point-of-care business," said the San Diego, California-based company's vice-chairman, president and CEO, Andre de Bruin. "The addition of this product line is expected to contribute to our near-term revenue and profit growth because it can be included within our existing sales and distribution structure." Financial details were not disclosed.
You may also be interested in...
The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.